FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from the ALINA study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell Carcinoma Who Are At Increased Risk for Disease Recurrence After Nephrectomy
Findings from the KEYNOTE-564 study
Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a Low Risk of Developing a Second Primary Breast Cancer In the First 10 Years After Diagnosis
Findings from the Young Women’s Breast Cancer Study
Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab as the Second-Line Treatment in Patients With Advanced Gastric/GEJ Adenocarcinoma
Findings from the PRODIGE 59-FFCD 1707-DURIGAST study
FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection Products
Additional safety information regarding the risk of serious adverse reactions related to fluorouracil use in patients with DPD deficiency became available since its approval
Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive Stage IB, II, or IIIA NSCLC
Findings from the ALINA study
Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly Improves the pCR in Locally Advanced Vulvar Squamous Cell Carcinoma
Findings from the NRG Oncology/GOG Study 279
EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab
Wyost is highly similar to the reference product Xgeva which was authorised in the EU in 2011
A Novel Model Helps Better Predict Risk of Cancer Development in Patients with Li-Fraumeni Syndrome
Better risk counselling may be achieved using the mathematical model
FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Solid Tumours
Evidence for efficacy is based on the results from the DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 studies
Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than with Anti-PD1 Therapy Alone, but the Occurrence of Adverse Events Is Also Higher
Findings from a pooled analysis of clinical trials conducted in patients with high-risk resectable melanoma
Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in Patients with Resectable NSCLC and Tumour PD-L1 Less Than 1%
Findings from a systematic review and meta-analysis